Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Publikováno v:
Hereditary Cancer in Clinical Practice
Background Little is known about the experience of young women who become aware of their parent’s BRCA1 or BRCA2 (BRCA) mutation status as adolescents or young adults. There is also currently a gap in the literature pertaining to those who are foun
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia
Autor:
Marcia Llacuachaqui, Jeffrey N. Weitzel, Steven A. Narod, Garrett P. Larson, Juan David Figueroa, Gonzalo Vásquez Palacio, Robert Royer, Song Li, Julián Esteban Londoño Hernández, Jorge Madrid, Mauricio Lema
Publikováno v:
Hereditary Cancer in Clinical Practice
Background Approximately 5% of all breast cancers can be attributed to a mutation in the BRCA1 or BRCA2 gene. The genetic component of breast cancer in Colombia has been, for the most part, studied on cases from the Bogota region. Five different foun
Autor:
Kukatharmini Tharmaratnam, Emma Hurley, Anthony J. Maxwell, Anthony Howell, Anne Irene Hagen, Marit Muri Holmen, Mary Wilson, Yit Yoong Lim, Dafydd Gareth Evans, Pål Møller, Elaine F. Harkness
Publikováno v:
Hereditary Cancer in Clinical Practice
Evans, D G, Harkness, E F, Howell, A, Wilson, M, Hurley, E, Holmen, M M, Tharmaratnam, K U, Hagen, A I, Lim, Y, Maxwell, A J & Moller, P 2016, ' Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality ', Hereditary cancer in clinical practice, vol. 14, 8 . https://doi.org/10.1186/s13053-016-0048-3, https://doi.org/10.1186/s13053-016-0048-3
Evans, D G, Harkness, E F, Howell, A, Wilson, M, Hurley, E, Holmen, M M, Tharmaratnam, K U, Hagen, A I, Lim, Y, Maxwell, A J & Moller, P 2016, ' Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality ', Hereditary cancer in clinical practice, vol. 14, 8 . https://doi.org/10.1186/s13053-016-0048-3, https://doi.org/10.1186/s13053-016-0048-3
Background The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast cancer. However, survival data fr
Autor:
Toomas Veidebaum, Jelena Aršavskaja, Aili Lilleorg, Krista Kaasik, Peeter Padrik, Andres Metspalu, Kristiina Tamboom, Mare Tekkel
Publikováno v:
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 8, Iss 1, p 4 (2010)
Hereditary Cancer in Clinical Practice, Vol 8, Iss 1, p 4 (2010)
Background The aim of this study was to identify BRCA1 and BRCA2 mutations in the Estonian population. We analyzed genetic data and questionnaire from 64 early-onset (< 45 y) breast cancer patients, 47 familial cases (patients with breast or ovarian
Autor:
Arvīds Irmejs, Arnis Āboliņš, Jānis Gardovskis, Dagnija Kalniete, Edvīns Miklaševičs, Ilze Strumfa, Miki Nakazawa-Miklasevica
Publikováno v:
Hereditary Cancer in Clinical Practice
Background Hereditary triple-negative breast cancer patients have better recurrence-free survival than triple-negative sporadic ones. High expression of some of the miRNAs is related to worse overall and disease-free survival of triple-negative breas
Autor:
Steven A. Narod
Publikováno v:
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 2, Iss 1, Pp 5-10 (2004)
Hereditary Cancer in Clinical Practice, Vol 2, Iss 1, Pp 5-10 (2004)
Options for the prevention of hereditary breast and ovarian cancer include screening, preventive surgery and chemoprevention. Screening studies with magnetic resonance imaging of the breast are promising but the technology is not widespread and MRI i
Autor:
Ewa Grzybowska, Małgorzata Krześniak, Wioletta Pekala, Jolanta Pamula, Helena Zientek, Marek Rusin
Publikováno v:
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 4, Iss 1, Pp 20-24 (2006)
Hereditary Cancer in Clinical Practice, Vol 4, Iss 1, Pp 20-24 (2006)
The 5' region of BRCA1 contains multiple regulatory sequences flanking the two alternative promoters α and β and two alternative, non-coding exons, 1a and 1b. Aberrations within the 5' region BRCA1 (encompassing two alternative promoters α and β
Autor:
Mirjana Brankovic-Magic
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 4, Iss 1, Pp 12-14 (2006)
Scopus-Elsevier
Hereditary Cancer in Clinical Practice
Scopus-Elsevier
Hereditary Cancer in Clinical Practice
Serbia and Montenegro is the most recent country to have joined the European integration processes in the Western Balkan region. War has troubled this country for more than ten recent years. Post-war conditions have been as severe as those during the
Autor:
Tadeusz Dębniak
Publikováno v:
Hereditary Cancer in Clinical Practice
Hereditary Cancer in Clinical Practice, Vol 5, Iss 2, Pp 97-116 (2007)
Hereditary Cancer in Clinical Practice, Vol 5, Iss 2, Pp 97-116 (2007)
Based on epidemiological data we can assume that at least some malignant melanoma (MM) and breast cancer cases can be caused by the same genetic factors. CDKN2A, which encodes the p16 protein, a cyclin-dependent kinase inhibitor suppressing cell prol
Autor:
Elizabeth Bancroft, Karolina Zieba, Margaret Christie, Esra Manguoğlu, Ros Eeles, Sarah Morgan, Paul Craven, R. Doherty, Jan Lubinski, Guven Luleci, Anita Mitra
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 4, Iss 2, Pp 111-112 (2006)
Scopus-Elsevier
Hereditary Cancer in Clinical Practice
Europe PubMed Central
Scopus-Elsevier
Hereditary Cancer in Clinical Practice
Europe PubMed Central
Prostate cancer is a significant public health problem. In the European Union, approximately 200,000 men are diagnosed annually and the incidence is increasing, even allowing for the rise in screen-detected prostate cancer. Multiple aetiologies have